Celon Pharma SA
WSE:CLN

Watchlist Manager

Celon Pharma SA

WSE:CLN

Watchlist

Dividends

Discount Rate

Price: 26.6 PLN 2.31% Market Closed

Market Cap: 1.4B PLN

Have any thoughts about
Celon Pharma SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US		Fubotv Inc NYSE:FUBO	Media
US		Bank of America Corp NYSE:BAC	Banking
US		Palantir Technologies Inc NYSE:PLTR	Technology
US	C	C3.ai Inc NYSE:AI	Technology
US		Uber Technologies Inc NYSE:UBER	Road & Rail
CN		NIO Inc NYSE:NIO	Automobiles
US		Fluor Corp NYSE:FLR	Construction
US		Jacobs Engineering Group Inc NYSE:J	Professional Services
US		TopBuild Corp NYSE:BLD	Consumer products
US		Abbott Laboratories NYSE:ABT	Health Care
US		Chevron Corp NYSE:CVX	Energy
US		Occidental Petroleum Corp NYSE:OXY	Energy
US		Matrix Service Co NASDAQ:MTRX	Construction
US		Automatic Data Processing Inc NASDAQ:ADP	Technology
US		Qualcomm Inc NASDAQ:QCOM	Semiconductors
US		Ambarella Inc NASDAQ:AMBA	Semiconductors

Add Price Alert

Price Target:

Last Price: 26.6 PLN

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

CLN Alert

Celon Pharma SA

26.6

+0.6 (+2.31%)

52 Week Range	14.1 32.3
Price Target

We'll email you a reminder when the closing price reaches PLN.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Fubotv Inc NYSE:FUBO	US
	Bank of America Corp NYSE:BAC	US
	Palantir Technologies Inc NYSE:PLTR	US
C	C3.ai Inc NYSE:AI	US
	Uber Technologies Inc NYSE:UBER	US
	NIO Inc NYSE:NIO	CN
	Fluor Corp NYSE:FLR	US
	Jacobs Engineering Group Inc NYSE:J	US
	TopBuild Corp NYSE:BLD	US
	Abbott Laboratories NYSE:ABT	US
	Chevron Corp NYSE:CVX	US
	Occidental Petroleum Corp NYSE:OXY	US
	Matrix Service Co NASDAQ:MTRX	US
	Automatic Data Processing Inc NASDAQ:ADP	US
	Qualcomm Inc NASDAQ:QCOM	US
	Ambarella Inc NASDAQ:AMBA	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Celon Pharma SA

What unique competitive advantages
does Celon Pharma SA hold over its rivals?

What risks and challenges
does Celon Pharma SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Celon Pharma SA.

What unique competitive advantages
does Celon Pharma SA hold over its rivals?

What risks and challenges
does Celon Pharma SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Celon Pharma SA.

Provide P/S
for Celon Pharma SA.

Provide P/E
for Celon Pharma SA.

Provide P/OCF
for Celon Pharma SA.

Provide P/FCFE
for Celon Pharma SA.

Provide P/B
for Celon Pharma SA.

Provide EV/S
for Celon Pharma SA.

Provide EV/GP
for Celon Pharma SA.

Provide EV/EBITDA
for Celon Pharma SA.

Provide EV/EBIT
for Celon Pharma SA.

Provide EV/OCF
for Celon Pharma SA.

Provide EV/FCFF
for Celon Pharma SA.

Provide EV/IC
for Celon Pharma SA.

Show me price targets
for Celon Pharma SA made by professional analysts.

What are the Revenue projections
for Celon Pharma SA?

How accurate were the past Revenue estimates
for Celon Pharma SA?

What are the Net Income projections
for Celon Pharma SA?

How accurate were the past Net Income estimates
for Celon Pharma SA?

What are the EPS projections
for Celon Pharma SA?

How accurate were the past EPS estimates
for Celon Pharma SA?

What are the EBIT projections
for Celon Pharma SA?

How accurate were the past EBIT estimates
for Celon Pharma SA?

Compare the revenue forecasts
for Celon Pharma SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Celon Pharma SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Celon Pharma SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Celon Pharma SA compared to its peers.

Compare the P/E ratios
of Celon Pharma SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Celon Pharma SA with its peers.

Analyze the financial leverage
of Celon Pharma SA compared to its main competitors.

Show all profitability ratios
for Celon Pharma SA.

Provide ROE
for Celon Pharma SA.

Provide ROA
for Celon Pharma SA.

Provide ROIC
for Celon Pharma SA.

Provide ROCE
for Celon Pharma SA.

Provide Gross Margin
for Celon Pharma SA.

Provide Operating Margin
for Celon Pharma SA.

Provide Net Margin
for Celon Pharma SA.

Provide FCF Margin
for Celon Pharma SA.

Show all solvency ratios
for Celon Pharma SA.

Provide D/E Ratio
for Celon Pharma SA.

Provide D/A Ratio
for Celon Pharma SA.

Provide Interest Coverage Ratio
for Celon Pharma SA.

Provide Altman Z-Score Ratio
for Celon Pharma SA.

Provide Quick Ratio
for Celon Pharma SA.

Provide Current Ratio
for Celon Pharma SA.

Provide Cash Ratio
for Celon Pharma SA.

What is the historical Revenue growth
over the last 5 years for Celon Pharma SA?

What is the historical Net Income growth
over the last 5 years for Celon Pharma SA?

What is the current Free Cash Flow
of Celon Pharma SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Celon Pharma SA.

P/E
Price to Earnings

-29.9

Current

-28.8

Median

21.9

Industry

Lower than median

Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E

-29.9

Market Cap

1.4B PLN

Net Income

-45.5m PLN

All Countries

Forward Multiples

			Market Cap	P/E
PL	C	Celon Pharma SA WSE:CLN	1.4B PLN	-29.9
JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	776 550.9T JPY	-5 347 888.9
US		Eli Lilly and Co NYSE:LLY	710.5B USD	84.9
UK		Dechra Pharmaceuticals PLC LSE:DPH	440.4B GBP	-15 783.5
DK		Novo Nordisk A/S CSE:NOVO B	3.3T DKK	35
US		Johnson & Johnson NYSE:JNJ	373.5B USD	25.4
US		Merck & Co Inc NYSE:MRK	251.1B USD	20.7
CH		Roche Holding AG SIX:ROG	202.7B CHF	17.6
CH		Novartis AG SIX:NOVN	183.3B CHF	11.6
UK		AstraZeneca PLC LSE:AZN	162.4B GBP	31.6
IE	E	Endo International PLC LSE:0Y5F	146B USD	-49.9

				Earnings Growth
PL	C	Celon Pharma SA WSE:CLN	Average P/E: 32.4 Negative Multiple: -29.9	N/A
JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	Negative Multiple: -5 347 888.9	N/A
US		Eli Lilly and Co NYSE:LLY	84.9	451%
UK		Dechra Pharmaceuticals PLC LSE:DPH	Negative Multiple: -15 783.5	N/A
DK		Novo Nordisk A/S CSE:NOVO B	35	86%
US		Johnson & Johnson NYSE:JNJ	25.4	-22%
US		Merck & Co Inc NYSE:MRK	20.7	7 321%
CH		Roche Holding AG SIX:ROG	17.6	32%
CH		Novartis AG SIX:NOVN	11.6	21%
UK		AstraZeneca PLC LSE:AZN	31.6	177%
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -49.9	N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

P/E

-67.5

2-Years Forward

P/E

38.4

3-Years Forward

P/E

1 248.4

Celon Pharma SA
WSE:CLN

P/E
Price to Earnings

P/E Forward Multiples

See Also

Company

Help

Tools

Stocks

Celon Pharma SA WSE:CLN

P/E Price to Earnings

P/E Forward Multiples

See Also

Company

Help

Tools

Stocks

Celon Pharma SA
WSE:CLN

P/E
Price to Earnings